Biogen Inc (BIIB34)

B3


	Symbol		Exchange		Currency
	BIIB34		B3		BRL	Delayed
	BIIB		NASDAQ		USD	Real-time
	0R1B		London		USD	Real-time
	1BIIB		Milan		EUR	Real-time
	BIIB		Xetra		EUR	Delayed
	BIIB		TradeGate		EUR	Delayed
	BIIB		Frankfurt		EUR	Delayed
	BIIB		Santiago		USD	Delayed
	BIIBm		Buenos Aires		ARS	Delayed
	BIIB		Vienna		EUR	Real-time

Currency in BRL

Disclaimer

173.75

+2.22(+1.29%)

Closed06:58:59

Fair Value

Day's Range

173.75

173.85

52 wk Range

168.30

225.00

BIIB34 Income Statement

Featured here, the Income Statement (earnings report) for Biogen Inc, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

Total Revenues

14,377.9

13,444.6

10,981.7

10,173.4

9,835.6

Total Revenues Growth

+6.88%

-6.49%

-18.32%

-7.36%

-3.32%

Cost Of Revenues

1,955.4

1,805.2

2,109.7

2,278.3

2,533.4

Gross Profit

12,422.5

11,639.4

8,872

7,895.1

7,302.2

Gross Profit Growth

+6.75%

-6.3%

-23.78%

-11.01%

-7.51%

Gross Profit Margin %

86.4%

86.57%

80.79%

77.61%

74.24%

Other Operating Expenses, Total

5,147.3

6,988.3

5,436.3

4,876.6

5,420

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-2.37%	+35.77%	-22.21%	-10.3%	+11.14%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	2,272.8	3,984.6	2,497	2,228.7	2,458.3
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	2,358.9	2,515.7	2,680.1	2,409	2,502.3
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	241.6	232.9	7.2	-7.4	218.8

Operating Income

7,275.2

4,651.1

3,435.7

3,018.5

1,882.2

Operating Income Growth

+14.32%

-36.07%

-26.13%

-12.14%

-37.64%

EBIT Margin %

50.6%

34.59%

31.29%

29.67%

19.14%

Net Interest Expenses

-67.4

-171.1

-239.4

-157.3

29.6

Net Interest Expenses Growth

+23.5%

-153.86%

-39.92%

+34.29%

+118.82%

Interest Expense, Total

-187.4

-213.1

-250.4

-246.6

-246.9

Interest And Investment Income

120

42

11

89.3

276.5

Other Non Operating Expenses, Total

-130.8

2.4

8.5

-40

-52.1

EBT, Excl. Unusual Items

7,077

4,482.4

3,204.8

2,821.2

1,859.7

Gain (Loss) On Sale Of Assets

-55.3

92.5

-

503.7

-

Other Unusual Items, Total

-152.2

-207.8

-599.8

-827.5

-

EBT, Incl. Unusual Items

7,046.5

5,052.8

1,780.1

3,594.4

1,296.8

EBT, Incl. Unusual Items Growth

+19.44%

-28.29%

-64.77%

+101.92%

-63.92%

EBT, Incl. Unusual Items Margin

49.01%

37.58%

16.21%

35.33%

13.18%

Income Tax Expense

1,158

992.3

52.5

632.8

135.3

Net Income to Company

5,888.5

4,060.5

1,727.6

2,961.6

1,161.5

Minority Interest

-

-59.9

-171.5

85.3

-0.4

Net Income

5,888.5

4,000.6

1,556.1

3,046.9

1,161.1

Net Income Growth

+32.9%

-32.06%

-61.1%

+95.8%

-61.89%

Net Income Margin %

40.96%

29.76%

14.17%

29.95%

11.81%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

5,888.5

4,000.6

1,556.1

3,046.9

1,161.1

Basic EPS - Continuing Operations

31.47

24.86

10.44

20.97

8.02

Basic EPS - Continuing Operations Growth

+45.55%

-21%

-58.02%

+100.92%

-61.73%

Diluted EPS - Continuing Operations

31.42

24.8

10.4

20.87

7.97

Diluted EPS - Continuing Operations Growth

+45.6%

-21.07%

-58.06%

+100.67%

-61.81%

Basic Weighted Average Shares Outstanding

187.1

160.9

149.1

145.3

144.7

Diluted Weighted Average Shares Outstanding

187.4

161.3

149.6

146

145.6

Dividend Per Share

-

-

-

-

-

Dividend Per Share Growth

-

-

-

-

-

EBITDA

7,739.9

5,108.3

3,923.4

3,536.9

2,377

EBITDA Growth

+10.34%

-34%

-23.2%

-9.85%

-32.79%

EBITDA Margin %